miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1

Cancer Research

Volumn 73, Issue 23, 2013, Pages 6972-6986

  Huang, Xiaoyong ^a   Taeb, Samira ^a   Jahangiri, Sahar ^a   Emmenegger, Urban ^a,b   Tran, Elisa ^a   Bruce, Jeff ^b,c   Mesci, Aruz ^a   Korpela, Elina ^a,b   Vesprini, Danny ^a,b   Wong, C Shun ^a,b   Bristow, Robert G ^b,c   Liu, Fei Fei ^b,c   Liu, Stanley K ^a,b  

^a Sunnybrook Health Sciences Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 95; SPHINGOLIPID; SPHINGOLIPID PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN TARGETING; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; TUMOR NECROSIS; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84890285272     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1657     Document Type: Article

References (49)

1. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and Bcl-2 immunoreactivity. J Urol 1998;159:1437-43.
2. Siders DB, Lee F. Histologic changes of irradiated prostatic carcinoma diagnosed by transrectal ultrasound. Hum Pathol 1992;23:344-51.
3. Leibovici D, Chiong E, Pisters LL, Guo CC, Ward JF, Andino L, et al. Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy. J Urol 2012;188:98-102.
4. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics: a comprehensive review. EMBO Mol Med 2012;4:143-59.
5. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-73.
6. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
7. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
8. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007;67:11111-6.
9. Niemoeller OM, Niyazi M, Corradini S, Zehentmayr F, Li M, Lauber K, et al. MicroRNA expression profiles in human cancer cells after ionizing radiation. Radiat Oncol 2011;6:29.
10. Metheetrairut C, Slack FJ. MicroRNAs in the ionizing radiation response and in radiotherapy. Curr Opin Genet Dev 2013;23:12-19.
11. Francia S, Michelini F, Saxena A, Tang D, de Hoon M, Anelli V, et al. Site-specific DICER and DROSHA RNA products control the DNA-damage response. Nature 2012;488:231-5.
12. Zhang X, Wan G, Berger FG, He X, Lu X. The ATM kinase induces microRNA biogenesis in the DNA damage response. Mol Cell 2011;41:371-83.
13. Lee KM, Choi EJ, Kim IA. microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 2011;101:171-6.
14. Ng WL, Yan D, Zhang X, MoY-Y, Wang Y. Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: M059J. DNA Repair 2010;9:1170-5.
15. Huang Z, Huang S, Wang Q, Liang L, Ni S, Wang L, et al. MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res 2011;71:2582-9.
16. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg 2009;33:698-709.
17. Li WG, Yuan YZ, Qiao MM, Zhang YP. High dose glargine alters the expression profiles of microRNAs in pancreatic cancer cells. World J Gastroenterol 2012;18:2630-9.
18. Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, et al. Delta-like ligand 4-notch blockade and tumor radiation response. J Natl Cancer Inst 2011;103:1778-98.
19. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 2011;71:2926-37.
20. De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 2011;103:645-61.
21. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009;10:578-85.
22. Arora H, Qureshi R, Jin S, Park A-K, Park W-Y. miR-9 and let-7g enhance the sensitivity to ionizing radiation by suppression of NF-κB1. Exp Mol Med 2011;43:298-304.
23. Gupta AK, Bakanauskas VJ, Cerniglia GJ, Cheng Y, Bernhard EJ, Muschel RJ, et al. The ras radiation resistance pathway. Cancer Res 2001;61:4278-82.
24. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
25. Kraemer A, Anastasov N, Angermeier M, Winkler K, Atkinson MJ, Moertl S. MicroRNA-mediated processes are essential for the cellular radiation response. Radiat Res 2011;176:575-86.
26. Zage PE, Sirisaengtaksin N, Liu Y, Gireud M, Brown BS, Palla S, et al. UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors. Cancer 2013;119:915-23.
27. Johnson KR, Johnson KY, Becker KP, Bielawski J, Mao C, Obeid LM. Role of human sphingosine-1-phosphate phosphatase 1 in the regulation of intra- and extracellular sphingosine-1-phosphate levels and cell viability. J Biol Chem 2003;278:34541-7.
28. Carlucci A, Porpora M, Garbi C, Galgani M, Santoriello M, Mascolo M, et al. PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells. J Biol Chem 2010;285:39260-70.
29. Pchejetski D, Bohler T, Stebbing J, Waxman J. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat Rev Urol 2011;8:569-678.
30. Mandala SM, Thornton R, Galve-Roperh I, Poulton S, Peterson C, Olivera A, et al. Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1-phosphate and induces cell death. Proc Natl Acad Sci U S A 2000;97:7859-64.
31. Bonnaud S, Niaudet C, Legoux F, Corre I, Delpon G, Saulquin X, et al. Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. Cancer Res 2010;70:9905-15.
32. Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M,et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963-70.
33. Nava VE, Cuvillier O, Edsall LC, Kimura K, Milstien S, Gelmann EP, et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 2000;60:4468-74.
34. Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O. First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther 2012;11:1841-51.
35. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 2006;118:1963-71.
36. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
37. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
38. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, et al. FTY720 (Fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res 2010;70:8651-61.
39. Paris F, Perez GI, Fuks Z, Haimovitz-Friedman A, Nguyen H, Bose M, et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med 2002;8:901-2.
40. Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000;6:1109-14.
41. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006;9:225-38.
42. Chae SS, Paik JH, Furneaux H, Hla T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest 2004;114:1082-9.
43. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449:682-8.
44. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, et al. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 2011;102:2264-71.
45. Chen Z-l, Zhao X-h, Wang J-w, Li B-z, Wang Z, Sun J, et al. microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem 2011;286:10725-34.
46. Zhou T, Zhang G, Liu Z, Xia S, Tian H. Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int J Colorectal Dis 2013;28:19-24.
47. Murakami Y, Tamori A, Itami S, Tanahashi T, Toyoda H, Tanaka M, et al. The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer 2013;13:99.
48. Yan L-X, Huang X-F, Shao Q, Huang M-Y, Deng L, Wu Q-L, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348-60.
49. Guo L, Huang Z-X, Chen X-W, Deng Q-K, Yan W, Zhou M-J, et al. Differential expression profiles of microRNAs in NIH3T3 cells in response to UVB irradiation. Photochem Photobiol 2009;85:765-73.